The avian hematopoietic system has long been an invaluable model to study the mechanisms of cell growth and differentiation. We have developed six MAbs against either chicken embryonic hematopoietic precursor cells or retrovirus-transformed cells. MAbs Mo1, Mo2, and Mo3 recognized transformation-associated markers expressed in AMV-transformed nonproducer cell line-BM2. Not only were these markers expressed 7 to 10 folds higher on BM2 than on normal monocytic cells, but their expression was drastically reduced when BM2 cells were induced to differentiate into macrophages by PMA. The control of marker expression is associated with v-myb-transforming cascade, since another monocytic lineage-specific oncogene, v-myc, did not enhance the expression of these markers. MAb Em1 detected a marker that is normally present in 20% of the cells from the 30/50% interface of a discontinuous percoll gradient of normal 4-day-embryo yolk sac. Its expression is also found in AEV-transformed cells and MSB1 cells. The epitope for Em1 was exposed after neuraminidase treatment on erythroleukemia cell line 6C2, which suggested that sialylation and/or glycosylation is pivotal in regulating the expression of specific markers in differentiation pathways during embryogenesis and tumorigenesis. MAb Em2 recognized proliferating hematopoietic cells after the fourth day of embryogenesis. MAb Em3, on the other hand, is presumed to be specific for an oncofetal antigen expressed in various transformed cells but only in 10% of the cells from 30/50% interface of a discontinuous percoll gradient of normal 4-day-embryo yolk sac. These MAbs will be useful for dissecting the expression of differentiation markers within normal versus abnormal differentiation pathways in molecular terms.